HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) All Versions of this Article: jnumed.108.051565v1 49/9/1529    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Related articles in JNM Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Mathews, W. B. Articles by Szabo, Z. Search for Related Content PubMed PubMed Citation Articles by Mathews, W. B. Articles by Szabo, Z.

Synthesis and In Vivo Evaluation of Novel PET Radioligands for Imaging the Endothelin-A Receptor

¹ Department of Radiology, Johns Hopkins University, Baltimore, Maryland; and ² Research and Development, Bristol-Myers Squibb, Princeton, New Jersey

Correspondence: For correspondence or reprints contact: William B. Mathews, Department of Radiology, Johns Hopkins University, 720 Rutland Ave., Ross 320, Baltimore, MD 21205. E-mail: bmathews{at}jhu.edu

The endothelin subtype-A (ETA) receptor is a member of a family of G-protein–coupled receptors that plays a central role in vasoconstriction, cell proliferation, and hormone production. The aim of this study was to synthesize and evaluate in vivo ¹¹C- and ¹⁸F-labeled analogs of the potent and selective ETA antagonist N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide (BMS-207940). Methods: Protected precursors and authentic nonradioactive standards were synthesized by reductive amination and subsequent alkylation of protected aldehyde 1. Desmethyl precursor 2 was reacted with ¹¹C-methyl iodide followed by deprotection and high-performance liquid chromatography purification to produce ¹¹C-(N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,1-methylindolecarboxamide) (¹¹C-BMS-5p) 3. Nitro precursor 4 was reacted with ¹⁸F-fluoride and purified by high-performance liquid chromatography to produce ¹⁸F-(N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,4-fluorobenzamide) (¹⁸F-FBzBMS) 5. Biodistribution was determined by injecting male CD-1 mice via the tail vein with either ¹¹C-BMS-5p 3 or ¹⁸F-FBzBMS 5. Specific binding was determined by pretreatment with 1 mg of BMS-207940 per kilogram. PET scanning of a baboon using either ¹¹C-BMS-5p 3 or ¹⁸F-FBzBMS 5 was performed at baseline and 40 min after intravenous administration of 1 mg of BMS-207940 per kilogram. Results: ¹¹C-BMS-5p 3 was synthesized with 1.5% radiochemical yield in 36 min, with an average specific activity of 1,051 GBq/µmol (28,400 mCi/µmol; n = 5) at the end of synthesis. ¹⁸F-FBzBMS 5 was synthesized with 0.54% radiochemical yield in 130 min, with an average specific activity of 12.9 GBq/µmol (349 mCi/µmol, n = 7) at the end of synthesis. In mice, the highest uptake of both radioligands was in the liver, lungs, and heart. Radioactivity in the liver washed out over time, and uptake in the lungs and heart remained relatively stable. Mice pretreated with 1 mg of BMS-207940 per kilogram showed greater than 64% specific binding in the lungs and kidneys at 60 min. Specific binding in the heart was determined to be 63% for ¹¹C-BMS-5p 3 and 81% for ¹⁸F-FBzBMS 5. PET studies in a baboon showed high uptake of both radioligands in the myocardium. Between 35 and 85 min, the heart-to-blood ratio was 4.7 to 1. Pretreatment with a 1 mg/kg dose of BMS-207940 showed 85% specific binding in the myocardium at 85 min after injection. Conclusion: Both ¹¹C-BMS-5p 3 and ¹⁸F-FBzBMS 5 bind selectively to the ETA receptor in vivo. Further development of these radioligands for imaging the ETA receptor in humans is warranted.

Key Words: antagonist • ¹¹C • ¹⁸F • endothelin • PET

COPYRIGHT © 2008 by the Society of Nuclear Medicine, Inc.

Related articles in JNM:

This Month in JNM

JNM 2008 49: 11A-12A. [Full Text]